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Abstract Cryptococcus spp. are considered ‘model yeasts’,
and the reasons for that are the topic of this review. Several
perspectives will be discussed, starting with their characteri-
zation and emergence as human pathogens before moving
onto their adaptations and the scientific response. The section
on characterization illustrates the progress of knowledge and
technology over the 120 years since Cryptococcus was first
identified, whilst the section on emergence sees this applied to
describe the expansion of the host population and environ-
mental niche. The ongoing outbreak in the Pacific northwest
of North America is discussed, including some of its drivers.
The section on adaptation highlights some insights into how
eukaryotes adapt both to their environment and within hosts,
and the final section covers the scientific response to this
threat in terms of treatment and prevention. The review
highlights both clinical and laboratory features of partic-
ular interest and places them into the wider context of
this still emerging threat.
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Cryptococcus spp. are considered ‘model yeasts’ by many
researchers—the reasons for that are the topic of this review.
Several perspectiveswill be discussed, startingwith their char-
acterization and emergence as human pathogens before mov-
ing onto their adaptations and the scientific response. The
section on characterization illustrates the progress of knowl-
edge and technology over the 120 years since Cryptococcus
was first identified, whilst the section on emergence sees this
applied to describe the expansion of the host population and
environmental niche. The ongoing outbreak in the Pacific
northwest of North America is discussed, including some of
its drivers. The section on adaptation highlights some insights
into how eukaryotes adapt both to their environment and with-
in hosts, and the final section covers the scientific response to
this threat in terms of treatment and prevention. It is beyond
the scope of the review to cover every aspect of cryptococco-
sis, and the intention is just to summarize current knowledge
of key topics and provide a starting point for further reading
about this fascinating, complicated and important human
pathogen.
A Model for Characterization
There are 70 species within the genus Cryptococcus. Two of
these, Cryptococcus neoformans and Cryptococcus gattii, ac-
count for almost all cases of human disease and are amongst
the most significant pathogenic yeasts in man, responsible for
a large burden of mortality and morbidity [1–3]. They are
widely dispersed throughout the environment; C. neoformans
is associated with avian guano [4], and C. gattii’s first identi-
fied environmental niche was the Australian Red River gum
tree [5, 6]—although both species have subsequently been
isolated from a wide variety of trees [7–9]. Their global dis-
tribution and ability to cause disease are driven by the species





1 CNS and HIV Infections Research Group, Oxford University
Clinical Research Unit, 764 Vo Van Kiet Street, Ward 1, District 5,
Ho Chi Minh City, Vietnam
2 Welcome Trust Major Overseas Programme Vietnam, Oxford
University Clinical Research Unit, 764 Vo Van Kiet Street, Ward 1,
District 5, Ho Chi Minh City, Vietnam
Curr Clin Micro Rpt (2015) 2:96–113
DOI 10.1007/s40588-015-0016-0
or varietal form; the vast majority of cases occur in immuno-
compromised hosts, although disease in the immunocompe-
tent is increasingly recognized [4, 10–12]. However, in gen-
eral Cryptococcus spp. are not considered to be primary hu-
man pathogens; rather, the ability to cause disease is an acci-
dental result of some adaptation to their usual saprophytic
niche.
Speciation
Cryptococcus neoformanswas first identified in 1894 follow-
ing isolation from peach juice [13, 14] and almost contempo-
raneously identified as a pathogen in a patient with osteomy-
elitis [15]. Unlike other Saccharomyces spp., the organisms
identified by Sanfelice and Busse did not ferment carbon
sources nor form ascospores—and for this reason in 1901,
they were transferred to the genus Cryptococcus [10]. The
Cryptococcus genus consists of basideomycetous sapro-
phytes, remarkable for their polysaccharide capsule, which
varies in size depending upon the environment in which the
yeast finds itself. The capsule is a key determinant of viru-
lence, and it is postulated that it enables survival of the yeast
within free-living amoebae or other simple organisms. The
capsule is easily identified on India Ink staining of clinical
specimens; characteristic budding is often seen.
Pathogenic Cryptococci can be distinguished serologically.
In 1935, Benham described serotypes A, B and C, using sera
raised from inoculated rabbits [16]. The resolution of this
methodwas improved by Evans in the 1950s [17, 18] enabling
the identification of serotype D in the late 1960s and a hybrid
form (AD) in the 1980s [19, 20]. Cryptoccoccus neoformans
var. grubii generally types as A, Cryptoccoccus neoformans
var. neoformans generally as D and Cryptococcus gattii types
as B or C—but there are exceptions which make serological
typing alone inadequate for accurate speciation [21].
Genotyping
Molecular typing techniques, notably restriction fragment
length polymorphism analysis [22], amplified fragment length
polymorphism analysis [23] and multi-locus sequence typing
[24] have generally supported and clarified the pre-existing
classification systems. However, they have also been instru-
mental in identifying new species, removing incorrect inter-
species distinctions and informing the decision to raise Cryp-
tococcus neoformans var. gattii from a varietal form to a spe-
cies in its own right [10, 25, 26•]. Earlier observations that
isolates were antigenically dissimilar, had different ecological
niches and caused a different spectrum of disease (see below)
have been validated by sequence-based technologies demon-
strating that the two forms are evolutionarily distinct [27, 28],
having diverged 40–80 million years ago [29, 30]. This prog-
ress demonstrates how advances in the technologies used for
classification have deepened the understanding of the genus
and how this genus can be used as a model for progressive,
systematic classification.
The polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) analysis of the URA5 gene has
been particularly useful [22]. This simple tool divides
C. neoformans into five genotypes (VNI-VNIV and VNB)
and C. gattii into four (VGI-VGIV). The genotypes provide
a basis fromwhich to understand phenotypes, correlating with
features such as outbreak epidemiology [10], antifungal sus-
ceptibility and virulence [31, 32]. However, recently, it has
been noted that these genotypes have variable degrees of ge-
netic heterogeneity, and some may benefit from subdivision
(e.g. VGII being divided into a, b and c in the Vancouver
Island outbreak—see below). Some genotypes may be suffi-
ciently distinct to be classified as varieties, or even ‘cryptic
species’—VG genotypes demonstrate distinctiveness at least
equivalent to that seen between C. neoformans vars. grubii
and neoformans [26•, 33, 34•]. Taxonomical debates continue
as classification systems keep pace with developing technol-
ogy [25, 35].
Metabolic Phenotype
Biochemical profiling can identify and distinguish
Cryptococcus species, with the most obvious example being
the use of Canavanine-Glycine-Bromothymol Blue (CGB)
Agar to distinguish C. neoformans from C. gattii—because
C. gattii is resistant to canavanine and can utilize glycine, its
successful growth effects a change in pH which turns the
medium blue, a pattern not seen with C. neoformans [36].
Other simple tests used for clinical identification include pro-
duction of urease and melanin [4]. Commercial identification
systems, such as API 20C AUX™ (bioMérieux SA, Marcy-
l’Etoile, France) and Vitek™ (bioMérieux Inc., Hazelwood,
USA) systems take advantage of species-specific carbohy-
drate utilization allowing cheap and rapid identification based
on biochemical profiling [37].
Proteome analysis promises to offer increased insights into
understanding the pathogenicity of complex organisms such
as Cryptococcus sp., where post-translational modification
may account for differences between strains [10, 38, 39].
Matrix-assisted laser desorption/ionization time of flight tech-
nology (MALDI-TOF) has made accurate quantification of
protein components readily available to research and clinical
laboratories. MALDI-TOF is cheap to perform, rapid and ca-
pable of high throughput [40]. Beyond use as a diagnostic
tool, such analyses can demonstrate how virulence factor ex-
pression is affected by exposure to stressors such as tempera-
ture, radiation or chemicals [38, 41–43, 44•]. An example is
how nitric oxide exposure results in upregulation of the anti-
oxidant agents thioredoxin and glutathione and oxidoreduc-
tases involved in the yeast stress response and also results in
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post-translational protein modification [42]. Mass spectral
technologies have also been applied to biofilms, which play
a role in cryptococcal virulence and have demonstrated that
biofilm organisms upregulate proteins associatedwith defence
(e.g. antioxidant, proteolytic or stress response proteins)
whilst downregulating proteins associated with development
(e.g. those responsible for translation, transcription and micro-
tubule formation) [44•]. Key outputs hoped for from these
new approaches are explaining mechanisms of drug resis-
tance, identifying markers of resistance and identifying new
drug targets [39, 45].
A Model for Emergence
Since its discovery, Cryptococcus has transformed from a rare
pathogen to one estimated to infect one million and kill over
600,000 individuals each year [1]. There are no accurate esti-
mates for the global incidence of non-HIV-associated crypto-
coccosis: sporadic cases in apparently immune-competent
hosts persist [2, 46–50], but in addition, large outbreaks in
immune-competent populations have recently been described
and are discussed below. The common driving factor behind
these areas of growth is exploitation of new niches, and the
most dramatic example of this is the HIV pandemic, which
continues to be the commonest risk factor globally. However,
in rich countries, ongoing emergence is increasingly driven by
non-communicable causes of immune deficiency [2, 46, 47,
50–52] including iatrogenic immunosuppression due to solid-
organ transplants or biological immunomodulatory therapies
[52–54].
Emergence of Cryptococcus neoformans as an Endemic
Pathogen
Recent developments in the understanding of the origin of the
AD hybrid serotype have led to the postulation that the evo-
lutionary source of C. neoformans is Africa. Cryptococcus sp.
has two mating types, α and a, and can exist in haploid or
diploid forms. In its haploid form, it demonstrates a single
mating-type allele (‘α’ (MATα) or ‘a’ (MATa) with the dip-
loid forms expressing one or both alleles (aa, αα, aα). Only
haploid cells mate, typically attracting their opposite mating
type with the secretion of pheromones, developing projections
and fusing to produce diploid progeny, which then quickly
divide by meiosis into four new haploid organisms, with vary-
ing degrees of recombination [4]. For convenience, these
forms are annotated as follows: for haploids, serotype X,
mating-type y (Xy); for diploids yXXy. So, serotype A with
the MATα mating-type allele (the commonest combination
globally [4]) would be Aα; serotype AD, with A carrying
the MATa mating-type allele and D the MATα, would be
aADα.
Interest in the origins of the AD hybrid resulted from the
anomalous fact that almost all global isolates of serotype A
demonstrate the MATα (Aα) mating-type allele [4], yet sero-
type AD, which is also globally distributed, frequently dem-
onstrates the serotype A MATa mating-type allele (aADα)
[55]. Various explanations were proffered, including the idea
that Aa became extinct overtime and that the aADα hybrid
predated this extinction. Another suggestion was that Aa had
an unidentified environmental niche or lacked virulence and
so was seldom isolated due to sampling bias.
However, the discovery of a genetically distinctive se-
rotype A (VNB genotype) subpopulation in Botswana
raised new and intriguing possibilities [24, 55]. The pro-
portion of C. neoformans var. grubii with the MATa allele
in Botswana is around 25 %, compared with a global
proportion of less than 0.1 %, and the population structure
shows a high degree of heterogeneity not seen in other
geographic regions [24]. In 2007, Litvintseva and col-
leagues used a combination of AFLP- and MLST-based
phylogenetic analyses to show that the Botswanan Aa was
very closely related to the Aa genes in global aADα hy-
brids from China, Europe and the USA [55]. They then
considered the impact of hybridization on fitness, using
UV irradiation as a stressful event and comparing the re-
sponse of Botswanan Aa and Aα isolates, with reference
Aα isolates, lab-generated aADα hybrids, wild-type
aADα hybrids and reference serotype D isolates.
Botswanan Aa isolates were more sensitive to UV radia-
tion than any other isolate, and hybridization with D con-
ferred significant UV resistance [55]. These two pieces of
information form the basis of the hypothesis that a large
proportion of the global AD population resulted from a
hybridization event in Botswana, producing a fitter organ-
ism, which was able to go on and colonize the world.
Colonization may have been facilitated by a combination
of the great human migrations, expansion of domesticated
pigeon populations and the huge expansion of international
trade in Africa driven by European imperialism [55–60]. This
theory has been further supported by research in Thailand,
where a genetic bottle neck, analogous to a founder effect,
was identified in C. neoformans var. grubii isolates [57].
Strong signatures of clonality were detected, with the null
hypothesis of random recombinations being rejected, in stark
contrast to the genetic heterogeneity seen in African isolates
[57]. The mean time to the most recent common ancestor was
estimated to be approximately 7000 years ago, well after the
currently estimated dates for the human out-of-Africa migra-
tion [58, 61, 62], suggesting Cryptococcus left Africa with
man, pigeons and perhaps other vectors to ultimately expand
clonally in new geographic locations. This ex-African
clonality has been described in multiple other geographic lo-
cations, and is believed to demonstrate an epidemic popula-
tion structure for the organism [12, 24, 63, 64].
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Emergence of Cryptococcus gattii as an Agent
of Outbreaks
Cryptococcus gattii is estimated to have diverged from
C. neoformans approximately 40 to 80 million years ago
[29, 65]. It was first described in 1970 in a Congolese patient
with cryptococcosis; the infecting isolate was found to have a
distinctively different morphology. Instead of the usual uni-
form round or oval forms seen with C. neoformans, this new
isolate produced frequent elongated or bacilliform
morphotypes [66, 67]. Subsequently, a number of human
cases were described in Australia, and pioneering work was
undertaken to identify its environmental niche [6, 68]. Follow-
ing extensive sampling of plants, their debris, soil and air, the
major niche was identified as the Red River Gum, Eucalyptus
camaldulensis. Since then, numerous other tree species have
been identified as habitats; the particular niche appears to be
rotting bark and wood, as well as soil beneath the canopy [8, 9,
34•, 69–73]. Historically, the incidence rates of C. gattii cryp-
tococcosis have been highest in Papua New Guinea (42.8/
million/year) and Australia’s Northern Territory (8.5/million
population/year) [74]. Unlike disease due to C. neoformans,
patients diagnosed with C. gattii usually have no identified
immune deficiency, and pulmonary involvement is more com-
mon [75, 76]. Host factors may have an impact on the risk of
disease—in Australia, the incidence rate in the aboriginal pop-
ulation is 10.4/million/year compared to the non-indigenous
population rate of 0.7/million/year, and the difference is not
thought to be wholly explained by differences in geography
[74].
It was previously believed that C. gattii was limited to the
tropics and subtropics, but it is increasingly being recognized
in temperate regions. The ongoing outbreak on Canada’s Van-
couver Island and in the Pacific northwest of the USA pro-
vides an excellent illustration of a pathogen exploiting a new
environmental niche; incidence there is now 25.1/million/year
[77].
The various C. gattii genotypes differ in their global distri-
bution, reproductive behaviour and pathogenicity. The VGII
genotype appears to be the oldest, estimated to have diverged
from a common ancestor 12.5 million years ago; VGIV di-
verged 11.7 million years ago; and VGI and VGIII diverged
from each other 8.5 million years ago [29]. VGI is the geno-
type most prevalent in Australasia and Europe, VGII is most
prevalent in South and North America (including the current
Pacific North West outbreak), VGIII is more common in
North and South America than other regions (but not predom-
inant), and VGIV is the most frequently described in Africa
[26•, 78]. The genotypic spread ofC. gattii andC. neoformans
is depicted in Fig. 1. The data (review by Cogliati, 2013)
contains a combination of human, veterinary and environmen-
tal samples from 2012 and earlier which were not necessarily
collected under formal surveillance nor randomized sampling
programmes. Despite these limitations, it is interesting to note
the regional variations, especially in C. gattii [79].
Vancouver Island Outbreak
Since 1999, there has been an outbreak of C. gattii disease
centred around Vancouver Island, Canada, and by 2009, it had
spread to northwestern USA [80]. This outbreak has largely
resulted from clonal expansions of three subtypes of VGII
(VGIIa, VGIIb and VGIIc). VGIIa dominates, and is termed
the ‘major’ strain. Laboratory models suggest it has enhanced
virulence—it replicates rapidly within macrophages, with a
high intracellular proliferation rate (IPR), and leads to shorter
survival times in the mouse infection model. Interestingly, this
increased virulence may in part be explained through muta-
tions in its mitochondrial genome [32, 81•]. Voelz et al. re-
cently clarified the previously described link between VGIIa’s
increased IPR and its capacity to transform its mitochondrial
morphotype to tubular (from globular) [81•]. It had already
been noted that a tubular mitochondrial morphotype was com-
moner in the pathogenic outbreak strain [32]. Using time-
lapse images, it was noted that VGIIa cells can rapidly
tubularize their mitochondria in response to oxidative stress,
becoming significantly less likely to be killed by the macro-
phage and yet slower to replicate than those with globular
mitochondria. The finding of reduced fecundity, in a strain
with a higher IPR, was explained by the observation that the
remaining yeast cells (with globular mitochondria) replicated
very rapidly. In the presence of the resistant but non-
replicative VGIIa tubular mitochondrial morphotype, even
non-outbreak strains are stimulated to increased IPRs, sug-
gesting a signalling pathway whereby yeast cells establish a
‘division of labour’ [81•]. This may have implications for
other infections and especially co-infections occurring in the
presence of C .gattii [81•].
VGIIb, which is termed the ‘minor’ strain, demonstrates
less virulence than VGIIa in both in vitro and in vivo models
[32, 82], although a difference in human outcomes has been
harder to demonstrate [77]. VGIIb is responsible for less than
10 % of cases in this outbreak, and because many of those
affected are in older age groups, it is difficult to compare
clinical outcomes [77]. VGIIc is similar to VGIIa genotypi-
cally and phenotypically but is unique to the USA. It was first
isolated in Oregon and appears to be the result of a recombi-
nation event, either locally or prior to import [32]. Currently in
Oregon, VGIIc causes 27 % of infections and VGIIa approx-
imately 63% [83•], compared to 0 and 86.3%, respectively, in
British Columbia [77].
The origin of the outbreak strains has been the source of
debate. Until recently, evidence was balanced between the
likeliest candidates: South America, Africa and Australia
(which all had evidence of recombination and genetic diver-
sity). However, recently, the case for South America has
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strengthened [29], due to the discovery of a strain displaying a
basal genetic lineage in virgin Amazonian rainforest, where
contamination from imported woods is thought extremely un-
likely [84].
Ultimately, it is hoped that better understanding the rela-
tionships between subtypes and the environmental niche will
enable the public health community to predict the likely range
of current outbreaks and regions at risk of outbreaks in the
future [85].
A Model for Adaptability
Virulence in Animal Hosts Results from Adaptation
for Survival in the Environment
Cryptococcus spp. are primarily environmental saprophytes.
Human-to-human transmission does not occur, and therefore
adaptive pressures that confer pathogenicity must come from
the non-human environment. It is widely held that the ability
to cause disease is due to the coincident pathogenic potential
of adaptations to its local environment: so-called ‘bystander
pathogenicity’ [86, 87]. C. neoformans possesses a variety of
specialized virulence factors, including an external polysac-
charide capsule, the ability to grow at mammalian body tem-
perature, production of laccase and melanin, and a number of
secreted factors (including phospholipase B and urease [88])
important for surviving the host immune response [10]. Al-
though Cryptococcus spp. can infect hosts ranging from
amoebae to mammals, there is no evidence that a susceptible
host is required at any stage of the life cycle. Even pigeons,
considered to have an important role in the global dispersal of
C. neoformans, are not susceptible to cryptococcosis so are
unlikely to exert evolutionary pressure [4, 89]. So, given the
myriad interactions between C. neoformans and other envi-
ronmental organisms, current data suggest that selection pres-
sures from environmental stress and predation have led to the
acquisition of a unique set of cryptococcal attributes, which
just happen to be useful in mammalian infection, rather than
there being some obligatory stage within a (as yet unidenti-
fied) mammalian host. Some of these attributes are described
below.
Uptake and Subsequent Intracellular Proliferation
Ruiz et al. (1982) observed that 99.9 % of C. neoformans
could be ingested and killed by Acanthamoeba palestinesis
trophozoites after 7 days and that it could also be ingested
by mites and sowbugs—all found in pigeon guano [90]. In-
gestion of C. neoformans by A. castellani is followed by in-
tracellular replication and the accumulation of cytosolic vesi-
cles containing shed capsular polysaccharide [91]. Replication
is impaired in mutants with deficient capsules or phospholi-
pase, and acapsular mutants are more readily killed after in-
gestion [92, 93]. Melanin production may also protect against
amoeba predation since, even in acapsular strains, melanized
individuals are more likely to survive ingestion [92, 93]. Thus,
factors associated with virulence in mammals may have
evolved to fulfil a role in cryptococcal interactions with
amoeba.
The interactions of C. neoformans with amoeba and host
macrophages are strikingly similar. In mammals,
C. neoformans is a facultative intracellular pathogen which
can survive phagocytosis by innate immune cells and prolif-
erate intracellularly [10]. The development of such transfer-
able intracellular survival skills may help to explain the broad
host range of C. neoformans: all major mammalian immune
responses rely on phagocytic effector cells. Following inva-
sion of the phagocyte by Cryptococcus, there may be dissem-
ination by non-lytic extrusion of yeast cells to both the extra-
cellular space and adjacent host cells (‘vomocytosis’) [92,
94–99]. This potential ‘Trojan horse’ effect may be the key
in establishing central nervous system infection [100–102].
Cryptococcus’ complex pattern of interaction with host innate
Fig. 1 Paired pie charts
representing the genotypic
distribution of C. neoformans
(left) and C. gattii (right) in North
America, South America, Europe,
Africa, Asia and Oceania. The
size of each chart represents the
number of genotyped isolates in
the analysis for that region, out of
a global total of 8077. Data from
Cogliati 2013 [79]
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immune cells is a key determinant of virulence—both intra-
cellular proliferation rate (IPR) and phagocytosis proclivity
have been correlated with mortality for C. gattii, and an en-
hanced ability to survive and replicate inside macrophages has
been shown to be associated with its spread in northwestern
North America and may even have triggered the outbreak [98,
101, 103–105].
For C. neoformans, in contrast to C. gattii, it seems initial
yeast uptake by macrophages, rather than IPR, correlates with
cerebrospinal fluid (CSF) fungal burden [103]. Infection with
high-laccase activity, high-uptake C. neoformans correlates
with higher pre-treatment fungal burden in patients’ CSF and
slower rates of fungal clearance with treatment [103]. In this
case, strains with smaller capsules are more readily engulfed by
macrophages and have enhanced intracellular survival.
Capsule
C. neoformans’ capsule is unique amongst human pathogenic
y e a s t s a n d i s c omp r i s e d o f p o l y s a c c h a r i d e s
(glucuronoxylomannan (GXM) and galactoxylomannan
(GalXM)) and a lesser proportion of mannoproteins (MP))
[106]. In addition to the effects on phagocytosis by amoebae
described above, the capsule may also protect against dehy-
dration and dessication in low humidity conditions [107].
The role of the capsule in pathogenesis and defence against
the mammalian immune response is well established [106,
108, 109]. Acapsular C. neoformans strains have reduced
pathogenicity in mice; the capsule promotes survival in their
lungs, dissemination to the brain and induces a more subdued
cellular response [110, 111]. The capsule also protects un-
opsonized yeasts from ingestion by phagocytes in vitro, de-
pletes complement components and impedes immune re-
sponse [112]. Capsular polysaccharide materials induce pro-
liferation and differentiation of normal CD4+ T cells into Th2
phenotype, favouring intracellular parasitism and dissemina-
tion [113]. The fact that acapsular C. neoformans strains are
only capable of causing prolonged brain infections in nude
mice (absent or deficient thymus) demonstrates the key role
of capsule in virulence [4]. Despite this, links between capsule
size and virulence were not demonstrated until recently when
a paper by Robertson et al. showed a larger ex vivo capsule
size was associated with higher opening CSF pressure and a
paucity of CSF inflammation [109]. They also showed that the
larger capsule size was associated with more shedding of cap-
sular antigens and viscosity of the CSF, which may be a mech-
anism for the elevated CSF pressure [109].
Growth at 37 °C
The ability to grow at mammalian body temperatures (37 °C
or higher) is an obvious yet essential attribute for any would-
be invasive fungal human pathogen [114–117]. There are
several explanations for the origin and evolution of thermo-
tolerance in C. neoformans. It has been hypothesized that a
bolide collision 65 million years ago eliminated a vast propor-
tion of the Earth’s fauna and triggered a global chain reaction
of volcanic and seismic activities, giving rise to a massive
fungal bloom that fed on decaying vegetation [114]. Under
these conditions, endothermy was a costly but effective adap-
tation for surviving mammals and birds species to offer pro-
tection against such a large fungal inoculum. Fungi would
have to adapt too to successfully infect, colonize and cause
disease in these new endothermic hosts [114]—however, this
adaptation would not be critical for an organism that does not
require mammalian hosts, so adaptations to warmer environ-
ments may offer a likelier explanation.
Strains ofC. neoformans have been shown to be able to grow
in a temperature range of 30 to 40 °C [117], but there is a con-
siderable variation in thermotolerance between different
C. neoformans strains, and some evidence that this is determined
by geographic origin. For instance, C. neoformans var.
neoformans strains, which in general are more susceptible to
high temperature than their globally distributed C. neoformans
var. grubii siblings, are more prevalent in temperate regions of
Europe [118]. Evidence that Cryptococcus spp. originated in
sub-Saharan Africa further supports the speculation that growth
at higher temperatures, essential for pathogenicity, is a survival
advantage that resulted from environmental selection pressures
in regions with higher ambient temperatures [7, 119].
Laccase and Melanin Production
Melanin is a brownish black pigment produced through oxi-
dative polymerization of phenolic compounds.C. neoformans
produces melanin with an oxidative enzyme called laccase
which synthesizes melanin from L-DOPA, dopamine, norepi-
nephrine and epinephrine [120–122]. Environmental isolates
ofC. neoformans are often melanized; melanization may have
evolved as a survival strategy to protect cells from UV radia-
tion and facilitate growth at extreme temperatures [123–125].
Defects in melanin production result in improved mouse sur-
vival in infection models [122] and have been shown to pro-
tect against enzymatic degradation, antimicrobial peptides,
oxidative stress and heavy metal toxicity [126, 27–129]. Of
note, it also decreases the efficacy of amphotericin B in vitro
[128]. Moreover, clinical isolates with higher laccase activity
have higher ex vivo CSF survival and are more resistant to
antifungal treatment [103].
Cryptococcus also Displays In-Host Adaptations
Morphology Switching
Cryptococcus spp. are capable of morphological transforma-
tions, and these can occur during infection. Such
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transformations include filament formation during mating,
and upregulation of capsule synthesis to produce giant cells
averaging 40–50 μm in diameter [93, 106, 130, 131] (see
Fig. 2), but up to 100 μm [132]. In mouse models, the giant
cell subpopulation can vary between 10 and 80 % of the total
pulmonary fungal population, depending on the duration of
infection, degree of inflammation and total fungal burden
[93]. Mice infected with a lower dose of yeasts, with less
inflammation, produce a higher proportion of giant cells
[93]. These giant cells are often polyploid but uni-nucleated,
suggesting DNA replication without subsequent completion
of mitosis and/or cytokinesis. This variable chromosomal
ploidy in the giant cell population indicates both dynamic
flexibility and stability of the cryptococcal genome [88, 93,
132].
Pheromone and cyclic AMP-dependent signalling path-
ways have been shown to be major regulators of cryptococcal
cell gigantism [88, 93, 133–135]. Temperature has been iden-
tified as a stimulus for this change in some strains [136]. The
formation of giant cells may be a survival strategy facilitating
evasion of host immune defences: giant cells are frequently
found in extracellular spaces and are more resistant to phago-
cytosis than regular yeast cells, perhaps representing an extra-
cellular subpopulation, co-colonizing with an intracellular
population of smaller cells which have utilized phagocytosis
to facilitate dissemination. Lower CSF fungal burdens in pa-
tients with chronic or latent (extra-CNS) infections are in
keeping with the observation that lower inocula seem to in-
ducemore gigantism [88], leaving fewer regular cells to hijack
macrophages to gain access to the CSF. Morphological het-
erogeneity presents an obstacle for the immune response,
which may explain some of the observed difficulties in cryp-
tococcal disease therapy [129].
Genome ‘Flexible Stability’ and Survival-Driven Adaptability
Early characterization of cryptococcal genomes came from
electrophoretic karyotyping [137]. Both the size and num-
ber of chromosomes were highly variable in clinical and
environmental isolates, suggesting extensive chromosomal
rearrangement and genomic flexibity [138]. Further inves-
tigation revealed the extent of variation within the popula-
tion and suggested meiotic-driven karyotypic variation
[139, 140]. Karyotype changes also occur within a single
infection; this was observed in a series of human cases and
confirmed in the mouse model [141]. Gross chromosomal
rearrangement has been observed in closely related strains
isolated from the same patient 77 days apart, further
supporting host-selective pressures as a driving force be-
hind this genome flexibility [142–144].
Ful l genome sequences became avai lable for
C. neoformans var. grubii in 2001 and C. neoformans
var. neoformans in 2005. Despite karyotypic variability,
these closely related varieties share over 80 % sequence
homology and are largely collinear [145] though not at
the subtelomeric regions, centromere or MAT loci [146].
The retention of such similarity is remarkable given their
separation over millions of years, and the combination of
genomic stability with the capacity to undergo extensive
chromosomal rearrangement upon selective pressure is
something of a paradox [142].
This genomic flexibility is likely a response to
within-host pressures and could be considered a
virulence-associated phenotype with possible conse-
quences for treatment. For example, the capacity for
aneuploidy may be a key factor in conferring resistance
to fluconazole [147–149]. This phenomenon is seen in
Candida albicans, where chromosomal rearrangement
and duplication is proposed as a mechanism allowing
populations to respond to selective pressures [150]. This
has been termed heteroresistance, whereby a subpopula-
tion of resistant organisms exists amongst a larger pop-
ulation of susceptible siblings, thanks to some degree of
genomic p la s t i c i t y. Va r ious s tud ies on azo le
heteroresistance in C. neoformans have demonstrated
disomy in chromosomes 1 and 4 occurring in resistant
subpopulations selected from growth conditions contain-
ing high antifungal drug levels [147, 151]. Resistant
clones emerging in media with the highest drug levels
were found to have disomies in four chromosomes:
Chr1, 4, 10 and 14 [147, 151]. Amplification of ATP
transporter efflux pump genes like Erg11 and Afr1 on
Chr1 was shown to correlate with azole resistance
[147], and disomy on Chr4 has been associated with
genes required for endoplasmic reticulum integrity under
azole stress [151]—there may be other mechanisms to
be discovered.
Fig. 2 India ink staining of a Vietnamese clinical isolates of
Cryptococcus neoformans var. grubii showing giant cells alongside
standard-sized counterparts. Image courtesy of Lam Tuan Thanh,
OUCRU, Vietnam
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A Model for Scientific Response
Medical research into the appropriate management of crypto-
coccal disease has increased rapidly since the advent of the
HIVepidemic [1]. Unlike many CNS infections, cryptococcal
meningitis is relatively easily diagnosed, with high fungal
burdens and a distinctive pathogen that can be seen with a
number of non-specific staining and culture methods or iden-
tified with highly sensitive antigen detection kits [4]. Howev-
er, outcomes remain unacceptably poor—with a 90-day case
fatality rate of up to 70 % [1, 3, 77, 152•]. Even when best
available treatments are provided in well-resourced settings,
mortality is upwards of 10–15 % [3, 77].
Antifungal Therapy—a Model for Clinical Research
Amphotericin B was the first treatment available for crypto-
coccosis and became available in the late 1950s [4]. The ar-
rival of fluconazole in the 1980s, with its excellent oral bio-
availability and tolerability, revolutionized treatment enabling
the shortening of duration of amphotericin treatment and the
long-term suppressive therapy required by immune sup-
pressed patients. There have been almost 40 randomized con-
trolled trials of antifungal therapy in cryptococcal disease,
although in general, these have been small (the median num-
ber of patients randomized is 58), and have not been powered
to survival (see Table 1). Rather, trials tended to use composite
endpoints consisting of survival, clinical improvement and
sterilization of cerebrospinal fluid. A major focus for the first
trials was testing increased doses of amphotericin, shortening
treatment regimens and combination treatment with
flucytosine [153–155].
A landmark paper was the 1997 AIDS Clinical Trials
Group and Mycoses Study Group study of 379 participants,
comparing treatment with higher dose amphotericin mono-
therapy to flucytosine combination therapy. This established
the amphotericin–flucytosine combination as the gold stan-
dard for HIV-infected patients with improved clinical and my-
cological outcomes; however, the trial lacked power to dem-
onstrate a survival effect [155]. Combination therapy has
formed the backbone of treatment recommendations since
then [156]. In 2013, the survival benefit was demonstrated
in a large trial from a single centre in Vietnam [152•].
Flucytosine also leads to improved outcomes and more rapid
fungal clearance when combined with fluconazole (compared
to fluconazole monotherapy), although studies have been
small [157–159]. Unfortunately, access to both amphotericin,
and in particular flucytosine, is extremely poor in the locations
where most disease occurs [160]. Direct comparisons of non-
amphotericin containing combination treatments with
amphotericin-based combination treatments are underway
[161].
In settings where flucytosine is not available, the
combination of amphotericin with fluconazole is recom-
mended [156], although there is no clear evidence that
this improves mortality. Patients receiving 2 weeks of
induction treatment with amphotericin combined with
fluconazole had similar outcomes at 10 weeks and
6 months to patients receiving 4 weeks of amphotericin
monotherapy [152•].
Trials in cryptococcal disease are challenging. HIV-
infected patients are complex with multiple health needs and
require prolonged follow-up; this in part explains the relative
paucity of data to inform treatment decisions. The develop-
ment of early fungicidal activity (EFA) as a measure of treat-
ment effect offers the chance to speed treatment development.
Following its conception in Thailand and its subsequent use in
numerous intervention studies, there is hope that it will even-
tually serve as a robust surrogate marker of the efficacy of
antifungal treatments [162–167]. Differences in EFA provide
biological plausibility for the differences in survival seen with
different treatments in the Vietnamese study [152•].
Table 1 Cryptococcal trial
summary statistics as of 1979–
2014
Factor Value
Estimated number of cases of CM per year in HIV patientsa 957,900
Estimated number of CM deaths per yeara 624,700
Number of patients with CM randomized in treatment trials 3182
Studies powered to mortality 1
Studies that have shown a mortality difference 3
Number of randomized controlled trials (RCTs) in cryptococcal meningitis 35
Median number of patients per RCT 58
Percentage of trials with less than 100 patients 75
Percentage of trials in HIV patients 92
Median days from receipt of funding to randomizing first patient in a trialb 611
a Estimates from Park et al, AIDS 2009
b Refers to any clinical intervention trial in any disease
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Adjuvant Therapies
Because of a lack of new antifungal agents, several
groups have undertaken research seeking options for
adjuvant therapies including corticosteroids [168],
IFN-γ [169, 170•] and acetazolamide [171]. Results
from the corticosteroid trial are yet to be published,
IFN-γ has been shown to have a statistically significant
impact on EFA (but not mortality) and the acetazol-
amide trial was discontinued early due to an excess of
adverse advents, likely due to additive toxicity with
amphotericin. Currently, none of these adjuvants can
be recommended in routine clinical care.
The timing of initiation of antiretrovirals (ARVs) in HIV
co-infection has been a key area of interest over recent years,
with a need to balance the benefits of ARVs (especially with
regards to opportunistic infections) with the possible harmful
consequences of immune reconstitution syndromes. In pulmo-
nary tuberculosis, early initiation appears to be beneficial, al-
though this effect was not seen in a randomized trial in TB
meningitis [172–175]. In cryptococcal meningitis, the COAT
trial (2014) found that early initiation of ARVs was associated
with an increased risk of death and appeared to carry no ben-
efit in terms of reduced incidence of opportunistic infections
[176•]. Previous smaller studies also suggested probable in-
creased risks of harmwith early initiation of ARVs [177, 178].
It is hypothesized that the increase in mortality is related to
immune reconstitution inflammatory syndrome (IRIS) and
that the impact is greater earlier in the course of treatment,
when the patient has not yet begun to recover from the original
intracerebral insult and has limited reserves. In keeping with
this theory, Boulware et al. noted that the increased mortality
was especially pronounced in patients with a baseline CSF
white cell count <5 cells/mm3 [176•], an established risk fac-
tor for IRIS [179, 180].
Perhaps the most valuable adjuvant in the treatment
of cryptococcal meningitis is the management of raised
intracranial pressure. International guidelines recommend
that pressure should be maintained below 25 cm of
CSF, with daily lumbar punctures if necessary [181].
Pressure is elevated at presentation in over half of pa-
tients [152•, 176•, 182], and failure to comply with
management guidelines has been associated with ad-
verse outcomes [183]—fears about frequent lumbar
punctures leading to harm appear to be unfounded
[184, 185]. However, there have not been any prospec-
tive trials comparing different pressure management
methods.
A Model of Early Detection and Treatment
Current antifungal and adjuvant options have yet to achieve
the large reductions in mortality required in cryptococcal
meningitis but perhaps an upstream approach could. Early
diagnosis is invariably beneficial in the management of infec-
tious diseases, and there is much interest in the use of lateral
flow antigen (LFA) detection test for cryptococcal antigen
(CrAg) to diagnose a pre-symptomatic stage of cryptococcal
meningitis where treatment efficacy may be improved. Un-
doubtedly, the LFA test brings opportunities to improve stan-
dard diagnostics in resource-limited settings [186], as it re-
quires little equipment, no electrical power and minimal train-
ing. CrAg positivity has been shown to predate symptoms of
cryptococcal meningitis by several weeks [187] and is associ-
ated with increased mortality [188, 189]. Modelling suggests
that systematic screening and treatment could be a cost-
effective intervention in selected patient populations
[190–192], and screening of asymptomatic patients is being
introduced in South Africa on a country-wide scale. However,
the best treatment for asymptomatic antigenaemia is un-
known. A prospective observational cohort suggested a ben-
efit of pre-emptive administration of fluconazole in such pa-
tients, but dosing schedules were uncontrolled and varied con-
siderably, preventing the formulation of a treatment recom-
mendation [190]. Further work in this area is urgently needed.
Another area of concern is illustrated in a study from Cambo-
dia which showed that many outpatients with antigenaemia,
without meningism, had evidence of disease on CSF exami-
nation [193]. An acceptable CrAg screening strategy would
need to ensure patients with cryptococcal meningitis (CM)
continued to receive evidence-based therapy.
A simplified but common format for a screen and treat
approach is depicted in Fig. 3 [194•]. Importantly, it acknowl-
edges that optimal treatment for asymptomatic antigenaemia
has not been established and that lumbar puncture should be
performed whenever feasible to exclude CM [195]. Such a
programme was predicted to be cost-effective in a Ugandan
study [190], and two studies in South East Asia suggested
implementation would cost less than 300 USD per life year
gained (depending on actual prevalence of CrAg positivity,
and fluconazole drug costs)—even at the top end of this range,
the intervention would be classified as ‘very cost-effective’
under WHO guidelines [191, 192].
However, when implemented in an ambulatory care setting
in Kenya, 782 patients were enrolled into the screen and treat
intervention and offered high-dose fluconazole followed by a
maintenance dose if they tested positive. Unexpectedly, the
study failed to demonstrate any overall mortality benefit to
the intervention. The study was compromised by poor uptake
of the intervention and the fact that historical controls were
used, but in this ‘real world’ setting, there was little to suggest
any benefit [196•]. A different approach in Tanzania, where a
universal screening of hospitalized HIV patients was under-
taken, failed to improve diagnostic accuracy beyond standard
of care and did not demonstrate a mortality benefit [197]. In
both studies, due to local resource issues, all patients received
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fluconazole monotherapy even if meningitis was diagnosed—
mortality was high in CM patients, and inadequate drug ther-
apy may have masked any mortality gains from early diagno-
sis, even though the proposed benefit from preventing cases of
CM should have been realized.
Cryptococcal infections are challenging to manage, and
there is a value in considering the story of the scientific re-
sponse when considering how to respond to future emerging
infections. Firstly, the diagnostic tests and treatments must be
available where the burden of disease is highest, and ideally,
research should be undertaken in these settings [198]. Second-
ly, trials should be powered for relevant clinical endpoints
until surrogate endpoints have been conclusively validated.
Finally, it shows the importance of having proposed preven-
tative medicine interventions such as early initiation of ARVs
and pre-symptomatic screening trialed in a robust, real-world
setting before they are rolled out, as results can be unexpected.
Conclusion
Cryptococcus spp. are consideredmodel yeasts for a variety of
reasons: disease is relatively easy to diagnose; a wide-variety
of laboratory models of infection have been developed; organ-
isms are convenient to keep and grow in laboratory environ-
ments; and they are well characterized as a result of their major
public health impact and disease is severe, so the impact of an
intervention is readily measured.
Cryptococcosis remains a challenging condition which is
unlikely to go away whilst populations of iatrogenically im-
munosuppressed hosts increase and the pathogen itself con-
tinues to adapt to new environments and hosts. The high mor-
tality associated with best available treatment demands that
further therapeutic trials are undertaken with new antifungals
or adjuvants. Adaptive trial designs and international
collaborations should allow these to be powered to clinically
relevant endpoints until such a time as surrogate endpoints
have been validated.
A further ongoing focus should be systems-based ap-
proaches to earlier diagnosis, such as LFA screening—but
these must be clearly evaluated for benefits in real-world set-
tings. As cryptococcal disease continues to emerge; ongoing
research should see the development of models and ap-
proaches likely to be transferable to other pathogens in the
future. Monitoring the trajectory of its adaptations to new
environments and new hosts will allow health care planners
to consider its likely future impact. Together, these measures
will hopefully address the unacceptably high global mortality
and morbidity associated with this model CNS pathogen.
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